Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme

Biblos-e Archivo/Manakin Repository

Show simple item record

dc.contributor.author Valenzuela, Claudia
dc.contributor.author Torrisi, Sebastiano Emanuele
dc.contributor.author Kahn, Nicolas
dc.contributor.author Quaresma, Manuel
dc.contributor.author Quaresma, Susanne
dc.contributor.author Kreuter, Michael
dc.contributor.other UAM. Departamento de Medicina es_ES
dc.contributor.other Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP) es_ES
dc.date.accessioned 2020-12-09T08:46:42Z
dc.date.available 2020-12-09T08:46:42Z
dc.date.issued 2020-01-06
dc.identifier.citation Respiratory Research 21.1 (2020): 7 en_US
dc.identifier.issn 1465-993X es_ES
dc.identifier.uri http://hdl.handle.net/10486/692674
dc.description.abstract The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis (IPF), and increased our understanding of the underlying disease mechanisms. Nonetheless, many challenges and unmet needs remain in the management of patients with IPF and other progressive fibrosing interstitial lung diseases. This review describes how the nintedanib clinical programme has helped to address some of these challenges. Data from this programme have informed changes to the IPF diagnostic guidelines, the timing of treatment initiation, and the assessment of disease progression. The use of nintedanib to treat patients with advanced lung function impairment, concomitant emphysema, patients awaiting lung transplantation and patients with IPF and lung cancer is discussed. The long-term use of nintedanib and an up-to-date summary of nintedanib in clinical practice are discussed. Directions for future research, namely emerging therapeutic options, precision medicine and other progressive fibrosing interstitial lung diseases, are described. Further developments in these areas should continue to improve patient outcomes en_US
dc.description.sponsorship The page processing charges for this article have been paid by Boehringer Ingelheim. en_US
dc.format.extent 15 pag. es_ES
dc.format.mimetype application/pdf en
dc.language.iso eng en_US
dc.publisher BMC part of Springer Nature en_US
dc.relation.ispartof Respiratory Research en_US
dc.rights © 2020 The Authors en_US
dc.subject.other nintedanib en_US
dc.subject.other idiopathic pulmonary fibrosis en_US
dc.subject.other literature review en_US
dc.subject.other challenges en_US
dc.title Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme en_US
dc.type article en
dc.subject.eciencia Historia es_ES
dc.relation.publisherversion http://doi.org/10.1186/s12931-019-1269-6 es_ES
dc.identifier.doi 10.1186/s12931-019-1269-6 es_ES
dc.identifier.publicationfirstpage 7-1 es_ES
dc.identifier.publicationissue 1 es_ES
dc.identifier.publicationlastpage 7-15 es_ES
dc.identifier.publicationvolume 21 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion en
dc.rights.cc Reconocimiento es_ES
dc.rights.accessRights openAccess en
dc.authorUAM Valenzuela, Claudia (325130) es_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record